CEACAM5 and familial pancreatic carcinoma: For one individual in our study diagnosed with stage 4 pancreatic cancer, CEACAM5 was a persistent outlier (9.7–10.7 MAD) in plasma for four consecutive samples, collected 16.5, 12.5, 8.0, and 3.5 months pre-diagnosis.